Serum antibodies to pneumococcal neuraminidase NanA in relation to pneumococcal carriage and acute otitis media.
Pneumococcal neuraminidase, NanA, is a pneumococcal vaccine candidate. Prior culture-confirmed pneumococcal contacts were shown to induce serum anti-NanA antibodies during the first 2 years of life. The antibody concentrations at neither 12 nor 18 months were significantly associated with the risk of subsequent pneumococcal carriage or acute otitis media.
Simell
Birgit
B
Vaccine Immunology Laboratory, National Public Health Institute, Mannerheimintie 166, 0300 Helsinki, Finland. birgit.simell@ktl.fi
Jaakkola
Teija
T
Lahdenkari
Mika
M
Briles
David
D
Hollingshead
Susan
S
Kilpi
Terhi M
TM
Käyhty
Helena
H
D000208:Acute Disease; D000328:Adult; D002353:Carrier State / Q000097:blood / Q000276:immunology* / Q000635:transmission*; D002675:Child, Preschool; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007223:Infant; D009439:Neuraminidase / Q000276:immunology*; D010033:Otitis Media / Q000097:blood / Q000276:immunology*; D011008:Pneumococcal Infections / Q000097:blood / Q000276:immunology* / Q000635:transmission*; D013296:Streptococcus pneumoniae / Q000201:enzymology* / Q000276:immunology
D007074:Immunoglobulin G; D009439:Neuraminidase